MedTrace Logo

N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography

NCT00830193 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2009-01-27

No results posted yet for this study

Summary

Critically ill patients frequently undergo contrast enhanced computed tomography (CT) to establish diagnoses and direct management. Contrast agents can disturb kidney function and result in kidney dysfunction. The investigators investigated the effects of high dose N-acetylcysteine (NAC) or placebo, in addition to hydration, in preventing kidney dysfunction following contrast enhanced CT) in critically ill adults in the intensive care units of two teaching hospitals.

Conditions

  • Contrast Induced Nephropathy
  • Critically Ill

Interventions

DRUG

N-acetylcysteine

Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).

DRUG

D5W Placebo

Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).

Sponsors & Collaborators

  • Martin, Claudio M., M.D.

    collaborator INDIV

  • Fran Priestap

    collaborator UNKNOWN

  • Unity Health Toronto

    lead OTHER

Principal Investigators

  • Claudio M Martin, MD, FRCPC, MSc · London Health Sciences Centre - Victoria Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830193 on ClinicalTrials.gov